Y-mAbs Therapeutics (YMAB) Stock Price, News & Analysis

Company Overview

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

Key Stats

• Today's Range: $10.59 to $11.66
• 50-Day Range: $11.14 to $15.69
• 52-Week Range: $5.04 to $20.90
• Volume: 699,093 shs
• Average Volume: 242,513 shs
• Market Capitalization: $498.96 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $21.14
• Consensus Rating: Moderate Buy

Y-mAbs Therapeutics Stock Analysis - MarketRank™

Y-mAbs Therapeutics scored higher than 60% of companies evaluated by MarketBeat, and ranked 494th out of 971 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Y-mAbs Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 6 buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Y-mAbs Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Y-mAbs Therapeutics are expected to grow in the coming year, from ($0.64) to ($0.42) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Y-mAbs Therapeutics is -20.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Y-mAbs Therapeutics is -20.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Y-mAbs Therapeutics has a P/B Ratio of 5.41. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.84% of the float of Y-mAbs Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Y-mAbs Therapeutics has a short interest ratio ("days to cover") of 15, which indicates bearish sentiment.

Change versus previous month

Short interest in Y-mAbs Therapeutics has recently decreased by 5.65%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Y-mAbs Therapeutics does not currently pay a dividend.

Dividend Growth

Y-mAbs Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

10.84% of the float of Y-mAbs Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Y-mAbs Therapeutics has a short interest ratio ("days to cover") of 15, which indicates bearish sentiment.

Change versus previous month

Short interest in Y-mAbs Therapeutics has recently decreased by 5.65%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.34

News Sentiment

Y-mAbs Therapeutics has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 13 news articles for Y-mAbs Therapeutics this week, compared to 3 articles on an average week.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Y-mAbs Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,338,100.00 in company stock.

Percentage Held by Insiders

22.50% of the stock of Y-mAbs Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

70.85% of the stock of Y-mAbs Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

YMAB Stock Analysis - Frequently Asked Questions

How have YMAB shares performed this year?

Y-mAbs Therapeutics' stock was trading at $6.82 at the start of the year. Since then, YMAB shares have increased by 63.3% and is now trading at $11.14.
View the best growth stocks for 2024 here.

How were Y-mAbs Therapeutics' earnings last quarter?

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) posted its quarterly earnings results on Friday, November, 8th. The company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by $0.02. The company earned $18.46 million during the quarter, compared to the consensus estimate of $23.38 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative trailing twelve-month return on equity of 24.61%.

When did Y-mAbs Therapeutics IPO?

Y-mAbs Therapeutics (YMAB) raised $80 million in an IPO on Friday, September 21st 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity served as the underwriters for the IPO and BTIG was co-manager.

Who are Y-mAbs Therapeutics' major shareholders?

Y-mAbs Therapeutics' top institutional investors include State Street Corp (2.70%), Caligan Partners LP (2.67%), Geode Capital Management LLC (1.82%) and Charles Schwab Investment Management Inc. (0.63%). Insiders that own company stock include Biotech Aps Wg, Johan Wedell-Wedellsborg, Bo Kruse, Thomas Gad, Vignesh Rajah and Joris Wilms.
View institutional ownership trends.

How do I buy shares of Y-mAbs Therapeutics?

Shares of YMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Y-mAbs Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Y-mAbs Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), e.l.f. Beauty (ELF), Adobe (ADBE) and Jabil (JBL).

Company Calendar

• Last Earnings: 11/08/2024
• Today: 11/17/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/06/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:YMAB
• CUSIP: N/A
• CIK: 1722964
• Web: www.ymabs.com
• Phone: (646) 885-8505
• Fax: N/A
• Employees: 150
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $21.14
• High Stock Price Target: $26.00
• Low Stock Price Target: $11.00
• Potential Upside/Downside: +89.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.88
• Research Coverage: 8 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.54)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-21,430,000.00
• Net Margins: -28.22%
• Pretax Margin: -27.28%
• Return on Equity: -24.61%
• Return on Assets: -18.49%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.92
• Quick Ratio: 2.72

Sales & Book Value

• Annual Sales: $84.82 million
• Price / Sales: 5.88
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.06 per share
• Price / Book: 5.41

Miscellaneous

• Outstanding Shares: 44,790,000
• Free Float: 34,711,000
• Market Cap: $498.96 million
• Optionable: Optionable
• Beta: 0.68